Provider Experience With the Use of Ketamine for Refractory Status Epilepticus
Tantillo G, Davis N, Granstein J, Yoo J, Agarwal P, Reilly K, Reynolds A, Kayal G, Liang J, Jetté N. Provider Experience With the Use of Ketamine for Refractory Status Epilepticus. Clinical Neuropharmacology 2024, 47: 37-43. PMID: 38478363, DOI: 10.1097/wnf.0000000000000582.Peer-Reviewed Original ResearchConceptsRefractory status epilepticusStatus epilepticusPerceived contraindicationsUse of vasopressorsFirst-line agentsRefractory status epilepticus treatmentSecond-line agentsAssociated with complicationsElevated intracranial pressureNeurocritical Care SocietyRespiratory depressionHeart failureEEG monitoringHemodynamic supportOptimal doseKetamine useSeizure controlIntracranial pressureControl seizuresDecreased needKetamine usersAmerican Epilepsy SocietyKetamineAmerican AcademyAnesthetic agentsHealth care access, psychosocial outcomes and mental health in adults living with epilepsy during the COVID-19 pandemic
Mc Carthy L, Mathew B, Blank L, Van Hyfte G, Gotlieb E, Goldstein J, Agarwal P, Kwon C, Singh A, Fields M, Marcuse L, Yoo J, Sivarak E, Gururangan K, Navis A, Jetté N. Health care access, psychosocial outcomes and mental health in adults living with epilepsy during the COVID-19 pandemic. Epilepsy & Behavior 2024, 151: 109617. PMID: 38219607, DOI: 10.1016/j.yebeh.2023.109617.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-9Generalized Anxiety Disorder-7Psychosocial outcomesMental healthHealthcare accessCancelled visitsCross-sectional study of adultsHealth care accessCOVID-19 pandemicMental health comorbiditiesPoor mental healthSocial support issuesPoor psychosocial outcomesSymptoms of anxietyCross-sectional studyStudy of adultsCare accessPsychosocial supportHealth comorbiditiesModerate/severe depressionHealth systemTelehealth visitsNeurological carePLWEStandardized questionnaire